Market Overview

Endo Health Solutions to Buy Boca Pharmacal for $225M

Share:
Related ENDP
Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil
Watch Out Below, Endo International Investors, Management Is Doubling Down On Weak Assets

Endo Health Solutions (NASDAQ: ENDP) today announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash.  The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company.

Posted-In: News M&A

 

Related Articles (ENDP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters